This is a StreetInsider.com Premium Only Page

iBio, Inc. (IBIO) – Press Releases

Mar 26, 2024 07:35 PM iBio Announces $15.0 Million Private Placement

Sep 27, 2023 04:19 PM iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Jun 27, 2023 08:00 AM iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

Jun 12, 2023 04:15 PM iBio Forges Research Collaboration with the National Institutes of Health

Jun 6, 2023 08:00 AM iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline

May 9, 2023 04:30 PM iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023 04:05 PM iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023 08:10 AM iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023 04:47 PM iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Jan 5, 2023 08:00 AM iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine

Dec 9, 2022 04:05 PM iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022 11:27 PM iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022 04:01 PM iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022 08:00 AM iBio to Participate in the JMP Securities Hematology and Oncology Summit

Dec 5, 2022 08:00 AM iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 2, 2022 04:30 PM iBio Announces CEO Departure

Nov 3, 2022 08:00 AM iBio Accelerates Transformation to AI-Powered Biotech

Sep 27, 2022 04:10 PM iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Sep 21, 2022 08:30 AM iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

Aug 16, 2022 09:00 AM iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

May 18, 2022 08:00 AM iBio to Participate in the H.C. Wainwright Global Investment Conference

May 12, 2022 04:05 PM iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022 08:00 AM iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

May 5, 2022 04:30 PM iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

May 2, 2022 08:00 AM iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Mar 11, 2022 08:00 AM iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Feb 15, 2022 08:00 AM Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

Feb 14, 2022 04:05 PM iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

Feb 7, 2022 04:30 PM iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

Jan 26, 2022 09:00 AM iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

Jan 4, 2022 04:30 PM iBio Announces Participation in the H.C. Wainwright BioConnect Conference

Dec 22, 2021 09:25 AM iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022

Dec 21, 2021 09:20 AM iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting

Dec 10, 2021 08:30 AM iBio Announces Partial Adjournment of Annual Meeting to December 22

Nov 30, 2021 08:00 AM ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting

Nov 29, 2021 08:45 AM Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

Nov 17, 2021 04:30 PM Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting

Nov 15, 2021 04:05 PM iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

Nov 15, 2021 01:00 PM iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

Nov 8, 2021 04:30 PM iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

Nov 3, 2021 04:47 PM iBio Acquires FastPharming Manufacturing Facility®

Oct 26, 2021 08:35 AM iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9

Sep 27, 2021 07:30 AM iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Sep 20, 2021 04:30 PM iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

Sep 20, 2021 07:30 AM iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021

Sep 7, 2021 04:30 PM iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

Aug 26, 2021 07:00 AM iBio Appoints William D. Clark to its Board of Directors

Aug 25, 2021 07:30 AM iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics

Jul 15, 2021 05:10 PM iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

Jul 8, 2021 04:15 PM iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs